Preclinical studies suggest that ketamine may reduce cancer cell proliferation and migration by lowering intracellular calcium levels and inhibiting HIF-1α, p-AKT, and p-ERK expression, thereby reducing VEGF levels [171,172]. The gene discussed is HIF1A; the disease is cancer.